Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach by Hodges, Mary Hamer et al.
RESEARCH ARTICLE
Lot quality assurance sampling to assess
coverage and compliance following mass
drug administration to eliminate lymphatic
filariasis in Fiji: A methodological approach
Milika Rinamalo1☯, Lorenzo Pezzoli2☯, Mike Kama1, Eric Rafai1, Ilisapeci Kubuabola3,
Mosese Salusalu3, Sung Hye Kim4¤*
1 Ministry of Health and Medical Services, Dinem House, Suva, Republic of Fiji, 2 Epidemiology Consultant,
London, United Kingdom, 3 College of Medicine, Nursing and Health Sciences, Fiji National University, Suva,
Republic of Fiji, 4 Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool,
United Kingdom
☯ These authors contributed equally to this work.
¤ Current address: Department of Environmental Biology and Medical Parasitology, Hanyang University




Assessing the quality of mass drug administration (MDA) rounds is a key component of lym-
phatic filariasis (LF) elimination programs. Routine collection of administrative coverage is
unreliable, especially when pockets with low program coverage exist. To address this gap,
we used lot quality assurance sampling (LQAS) following the 10th annual LF-MDA round in
Fiji to explore whether there was any area in which target coverage was not reached. We
also assessed the level of drug compliance and satisfaction with the LF-MDA implementa-
tion strategy.
Methodology/principal findings
We conducted a cross-sectional household survey in 3 divisions of Fiji. For LQAS, we
defined 19 lots in 7 medical areas of the Suva sub-division and another 12 sub-divisions in
the Central, Northern, and Eastern Divisions. A sample of 16 randomly selected household
members was taken un each lot. We defined our decision rule as follows: if more than 1 per-
son in a given lot did not swallow the medication, coverage was considered inadequate, i.e.
less than 80%.
Of the 7 lots in Suva sub-division and 12 lots in the 3 divisions, five and two lots, respec-
tively, were identified as having inadequate coverage. The overall program coverage esti-
mated from 304 samples was 92%, which was higher than the reported administrative
coverage of 82%. About 98% of interviewees were offered the medication and 96% swal-
lowed it. Non-participation arose from insufficient information on how to obtain the drugs. At
least 92% were satisfied with the LF-MDA implementation strategy.
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Conclusions
Areas of low program coverage with results discordant with the reported administrative cov-
erage existed in both urban and rural settings. Drug compliance and satisfaction were high,
even after repeated rounds. We recommend increasing efforts to deliver the service in
those areas with inadequate program coverage, as well as conducting timely coverage
assessment through LQAS for corrective action.
Introduction
Lymphatic filariasis (LF) is a mosquito-transmitted parasitic disease caused by the filarial nem-
atodes Wuchereria bancrofti, Brugia malayi and Brugia timori. It affects an estimated 120 mil-
lion people throughout the tropics and there are as many as 36 million cases of hydrocoele and
lymphoedema [1, 2]. In 1997, the 50th World Health Assembly (WHA) approved a resolution
calling for the elimination of LF as a public health problem by 2020 (WHA50.29). Shortly
after, the Global Program to Eliminate Lymphatic Filariasis (GPELF) was established. GPELF
aims to achieve the goal through annual rounds of single-dose mass drug administration
(MDA) of albendazole (one fixed dose of 400 mg) with diethylcarbamazine citrate (DEC, 6
mg/kg body weight) for at least 5–6 years [3], for those older than 2 years in countries where
onchocerciasis is not co-endemic. The current recommendation is that each LF-MDA round
should achieve epidemiological coverage of at least 65% of the at-risk population [4, 5].
The Pacific Program for the Elimination of Lymphatic Filariasis (PacELF) is the regional
arm of GPELF for the Pacific Island countries and Territories (PICTs) [6]. Sixteen of the 22
countries under PacELF were classified as endemic for LF following baseline prevalence sur-
veys conducted in 2000–2001 [6, 7]. Fiji is endemic for LF and has a total population of
885,000 (2017 estimate) scattered over more than 100 permanently inhabited islands [8]. W.
bancrofti, transmitted by Aedes polynesiensis, Ae. pseudoscutellaris and several other mosquito
species, is responsible for LF transmission in that country [3, 9]. Ae. polynesiensis is of particu-
lar concern in the region as there are currently no effective measures for controlling this vector
due to a trait called "limitation", that makes it highly efficient in transmitting LF even when the
prevalence within the population is low [10].
Historically, Fiji has the highest LF endemicity in the Pacific, and a long history of imple-
menting control measures [3, 9]. The country joined PacELF in 1999 and conducted a nation-
wide baseline blood survey on a sample of 5,983 people, which showed that 16.6% of the
survey participants were positive for circulating filariasis antigen (CFA), tested by the Binax
Now1 Filariasis Immunochromatographic Test (ICT) of Alere Scarborough (Scarborough,
ME) [7]. An LF-MDA round using the combination of DEC (6mg/kg) and albendazole 400mg
was commenced in 2002, covering 66% of the population, and was continued until 2006 [7].
An LF prevalence survey in 2007 estimated the national circulating antigen prevalence to be
9.5%, which triggered further consecutive rounds of LF-MDA from 2008 [11]. At the comple-
tion of another 5 rounds in 2012, an in-depth review by the national program determined that
a major issue was uncertainty about the extent of the actual LF-MDA program coverage
reached. Hence, a post-LF-MDA program coverage assessment was proposed to estimate the
real coverage in the population including the public’s compliance with the regimen, ideally by
sub-division, since the sub-divisions are highly heterogeneous.
Several methods have been proposed for assessing the coverage of public health interven-
tions; of these, the Lot Quality Assurance Sampling (LQAS) technique is useful in making
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accept/reject decisions as to whether an area has achieved a minimum level of coverage, while
requiring a relatively small sample size [12–14]. The LQAS is based on two coverage thresh-
olds, a lower threshold (LT), which is the minimum coverage level considered to be acceptable,
and an upper threshold (UT), which is generally the target coverage; it also specifies a lot sam-
ple size (N), and a decision value (d) [15]. If the number of untreated individuals detected in
the sample N is� d, the lot is "accepted", meaning that coverage is probably equal to or above
the LT. If the number of untreated people is > d, the lot is "rejected", meaning that coverage is
probably below the UT. Alpha is the probability of “accepting” a lot with low coverage; while
beta is the probability of “rejecting” a lot with high coverage [16]. The main advantage of
LQAS is the small sample size required to classify lots with regard to coverage levels. Although
this classification is binary (accept/reject) and doesn’t provide a coverage estimate [17], pro-
vided the lots (e.g. sub-divisions) cover a larger area (e.g. a division) and do not overlap, lot
data can be aggregated according to a stratified weighted design to estimate coverage in the
area [18].
We report on the first national assessment of LF-MDA program coverage in Fiji, which
used LQAS as a unique methodologic approach not only to obtain programmatic information
on areas with low program coverage but also to explore issues affecting the overall LF-MDA
implementation strategy at the national level; this should assist the Ministry of Health and
Medical Services (MHMS) in adjusting the strategy towards achieving the elimination goal.
The study was conceived and implemented before the global guidelines for coverage assess-
ment and tools for improving the quality of reported MDA data became available [19–21].
Materials and methods
Study area
Fiji is an island country located 2,000 km from the northeast of New Zealand, east of Vanuatu,
and west of Tonga, in the South Pacific. It is an archipelago of more than 300 islands, of which
one third are permanently inhabited by 837,271 residents [8] with a total land area of about
18,300 km2. Up to 87% of the population reside on the two major islands, Viti Levu and
Vanua Levu [8].
MHMS delivers health services throughout the four Health Divisions, Central, Eastern,
Western and Northern [22]. The Western Division consists of the dry western half of Viti
Levu, while the Central Division is the wet eastern half. Vanua Levu comprises the Northern
Division together with Taveuni Island. The remaining islands are grouped in the Eastern Divi-
sion (Fig 1). The provision of health services ranges from general to specialized clinical services
as well as public health programmes, with health personnel at nursing stations, health centres,
and sub-divisional and divisional hospitals (Fig 2) [22]. The Central/Eastern Division is the
largest by population size, up to 422,917, and caters to about 100 health facilities, with the
majority residing in the Suva sub-division [23]. The Northern Health Divisional office pro-
vides health services for 4 sub-divisions and there are about 50 health facilities for the popula-
tion of 135,282 as of the year 2015 [23]. For this survey, we defined the study area as the same
as that targeted by the 10th LF-MDA round, namely the 3 Health Divisions of Fiji (i.e. Central,
Northern and Eastern Divisions) (Fig 1).
Mass drug administration
An annual LF-MDA round was conducted in the three Health Divisions (13 sub-divisions) of
Fiji between 26th and 28th October 2012, administering albendazole 400mg and diethylcar-
bamazine citrate 6mg/kg to individuals over 2 years and not pregnant. The total number of
residents in the 3 divisions was 558,199, representing two-thirds of the national population
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[8]. By this round, all sub-divisions except the Northern Division had received 10 rounds of
LF-MDA. For each round, logistic arrangements, training, and supervision were organized by
the public health teams based in each sub-divisional Health Offices but coordinated by the
national LF elimination program at the Fiji Centre for Communicable Disease Control
(FCCDC).
Each sub-divisional health office conducted the training of trainers before the implementa-
tion of the LF-MDA round. The trainers were usually public health zonal nurses responsible
for any public health initiatives in each nursing zone. The nurses generally recruited and
trained the community volunteers who had represented certain localities on LF-MDA proce-
dures, such as registration of household members, offering medicine and completing the
Fig 1. Map of Fiji with 3 Health Divisions with households selected for the coverage assessment of the 10th round of LF MDA. The map was developed using ArcMap
10.4 (ESRI, Redlands, CA) and shapefiles from the GADM database of Global Administrative Areas, ver. 2.8 (gadm.org).
https://doi.org/10.1371/journal.pone.0238622.g001
Fig 2. Administrative levels of the health system designated by the Ministry of Health and Medical Services, Fiji [22].
https://doi.org/10.1371/journal.pone.0238622.g002
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forms in the booklets. Each community volunteer registered roughly 125 residents and was
tasked with administering medication to up to 100 residents via house-to-house visits during
the 3-day “Filariasis Free Weekend”. The registration booklets were distributed to these volun-
teers by zone nurses together with at least 1 bottle of 100 tablets of 400 mg albendazole and a
bottle of 1000 50mg DEC tablets. In addition, zone nurses and other health staff distributed
drugs at schools and designated fixed sites, such as health centers, markets, and universities.
Directly observed treatment (DOT) was applied to all participants and a fingernail of each per-
son’s left hand was marked with an indelible marker after having swallowed the drugs.
Study design
The LQAS survey was designed to assess whether there were any areas where LF-MDA pro-
gram coverage did not reach the predetermined goal at the sub-divisional or medical area level
set by the national LF elimination program, and to estimate program coverage and evaluate
the overall LF-MDA strategy.
The study area was comprised of 13 sub-divisions, of which there were 5 in the Central and
4 in the Northern Division, along with 4 sub-divisions in the Eastern Division. Each of the
sub-divisions in the study area was considered a lot in which a fixed number of individuals
would be randomly selected to respond to the survey questionnaire. As for the Suva sub-divi-
sion, whose population exceeds that of the Northern Division, we considered each of the 7
medical areas as lots. This yielded 19 non-overlapping lots, comprising 12 sub-divisions and 7
medical areas in 3 divisions.
Considering that the reported administrative coverage was 82% for the 3 divisions, the
LQAS for the LF-MDA coverage assessment, we set 80% as the lower threshold (the minimum
acceptable coverage by the national programme) and 95% as the upper threshold (the desired
coverage level). We chose alpha (the risk of "accepting" a lot when the actual program coverage
was low) to be lower than beta (the risk of "rejecting" a lot when the actual program coverage
was not low), assuming that the former is a greater risk for the population targeted. The result-
ing sample size (N) was 16, with a decision value (d) of 1, an alpha error of 19% and a beta
error of 14% (Sample LQ v1.10; Brixton Health, London, UK) [24] after comparing error levels
for sample sizes varying between 14 and 17.
Survey team organization and data collection procedure
The survey was conducted in March 2013, on average 163 days after the commencement of the
10th LF-MDA round in Fiji. Interviews lasted two to 28 minutes (mean duration: 5.5 minutes).
The survey teams worked in pairs, with at least one female member. The teams attended a
2-day training workshop before the initiation of fieldwork. The training covered the study
methodology and included implementation of a small pilot survey. The surveyors spoke both
English and Fijian and conducted the survey in a locality familiar to them. Each team was pro-
vided with a motor vehicle and tasked to survey a target of one lot of 16 households per day.
Per each lot, 16 sampling points (households) were selected using a multi-stage sampling
procedure: first, population size was used to choose the first 16 nursing zones from the list of
all nursing zones in each lot that was used by the national programme to estimate the quantity
of drugs for the LF-MDA round of the lot. Then, as each nursing zone was further divided into
specific localities (street, neighborhood, village, or settlement, etc.), the surveyors selected one
locality per nursing zone by simple random sampling. The third stage involved selecting one
household at random in that locality. For this purpose, the Family Profile Data register of all
families and members who reside in the locality, which is kept by Zone nurses at the Nursing
Stations, was used. However, when a Family Profile Data register was unavailable, the
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surveyors sketched a map of the locality, divided it into sectors of approximately equal sizes,
and chose one sector at random until each sector was comprised of around 20 households.
Finally, they selected one household at random from the list of 20 households. At the selected
household, only one eligible resident (> 2 years and not pregnant) was eventually randomly
selected for interview.
Subjects were interviewed by the surveyors using a standardized questionnaire. If a person
under the age of 12 was selected, the questionnaire was administered to the immediate guard-
ian in the household. No interview was conducted, if, in the selected household only ineligible
subjects were around, such as children under 2 years old or pregnant mothers, for the
LF-MDA duration, or no one was contactable on the day of the survey. Instead another house-
hold in the same locality was randomly selected.
Data management and statistical analysis
An Excel 2007 (Microsoft Corporation) worksheet was used to enter data, which was then
exported to Stata 12 (StataCorp LP, College Station, TX, USA) for analysis. The overall
LF-MDA program coverage was estimated using data from all lots as strata aggregated [25],
and the sizes of households and the ratio of the lot population to the total targeted population
were used to calculate survey weights in estimating the overall program coverage. Assuming
simple random sampling (SRS), 75% coverage, + 5% margin of error and a 95% confidence
level, the minimum sample size required to estimate coverage was 289. Hence, we were confi-
dent that our sample of 304 (19 multiplied by 16) individuals had higher power and/or preci-
sion [26] than the minimum sample needed. In order to achieve 95% confidence intervals (CI)
by category at the P<0.05 significance level, F ratios were obtained via adjusted Wald tests to
explore whether point prevalence estimates were the same across different categories.
Ethical considerations
Ethical approval for the survey was granted locally by the National Health Research Review
Committee, Fijian MHMS, as part of the standard procedure to evaluate the LF-MDA round.
The WHO Regional Office for the Western Pacific Ethics Review Committee (WPRO-ERC)
also reviewed and approved the study protocol (2013.21.FIJ.1.MVP). Participation was volun-
tary, and recruitment was undertaken with an introductory letter about the survey provided to
selected households. Written consent was obtained before the survey. Members of the house-
hold who were not present for the interview were excluded from the survey.
Results
Demographic characteristics of the survey participants
The study included 304 persons, from the same number of households, in three Health Divi-
sions of Fiji (Fig 1), with less than half residing in urban settings (Table 1). There was a slightly
higher percentage of females than males. Participants’ ages ranged from 2 to 88 years with a
median of 37 years. There was no significant difference in age between males and females
(P = 0.986) and the average number of eligible residents per household was 6.3.
LQAS for the 19 lots
Of the 19 lots tested by LQAS, seven were rejected, because at least two persons did not swal-
low their drugs, and were classified as having unacceptable coverage. In four (the Lami and
Makoi medical areas of the Suva sub-division, and the Naitasiri and Macuata sub-divisions) of
the seven rejected lots, the reported administrative coverage levels were above 80%; whereas in
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four (the Lakeba, Lomaiviti, Cakaudrove, and Tailevu sub-divisions) of the 12 accepted lots,
administrative coverage levels were below 80% (Table 2). In two of the rejected lots (Makoi
medical area and Macuata sub-divisions) the reported administrative coverage was above
100%.
Table 1. Demographic characteristics of respondents, and LF MDA coverage, in the Central, Northern, and Eastern Divisions of Fiji.
Variable Category Frequency Percentage� 95% CI� Coverage� 95% CI� P-value
Division Central 176 63.1 58.6–67.4 89.2 83.2–93.2 0.157
Northern 64 8.4 4.5–15.0 95.7 85.0–98.9
Eastern 64 28.5 25.5–31.7 97.2 84.2–99.6
Residence Urban 128 45.6 41.8–49.5 87.2 79.1–92.5 0.026
Rural 176 54.4 50.5–58.2 95.5 90.4–97.9
Sex Female 169 53.2 45.0–61.2 91.6 85.3–96.3 0.80
Male 134 46.8 38.8–55.0 92.5 85.2–95.4
Age <10 year 21 8.5 5.1–13.6 78.9 53.8–92.3 0.308
10–19 year 42 17.5 11.6–25.7 96.4 83.7–99.3
>19 241 74.0 65.9–80.7 92.1 87.0–95.3
Household size <5 persons 125 21.5 16.8–27.1 89.2 77.5–95.1 0.179
5–8 persons 155 69.2 61.6–75.9 90.1 84.8–94.6
9� persons 23 9.3 4.7–17.7 96.8 79.9–99.6
�Weighted based on the proportion of sub-divisional per divisional population size.
https://doi.org/10.1371/journal.pone.0238622.t001
Table 2. Results of the LQAS on sub-divisional LF-MDA coverage in the Central, Northern, and Eastern Divisions of Fiji.
Division Sub-division Medical area Population > 2 years old Administrative Coverage Have you swallowed LF-MDA drugs?
Yes No DK/NR D
Central Suva Suva 14,324 85.5% 15 1 0 A
Central Suva Raiwaqa 29,697 79.0% 13 2 1 R
Central Suva Samabula 16,297 90.6% 16 0 0 A
Central Suva Nuffield 44,618 58.6% 14 2 0 R
Central Suva Lami 28,282 83.9% 14 2 0 R
Central Suva Makoi 27,141 107.0% 12 3 1 R
Central Suva Valelevu 51,889 60.6% 13 3 0 R
Central Rewa - 77,504 84.8% 16 0 0 A
Central Naitasiri - 18,872 83.8% 12 4 0 R
Central Tailevu - 19,776 85.4% 16 0 0 A
Central Serua-Namosi - 30,369 91.0% 15 1 0 A
Northern Bua - 15,284 92.1% 16 0 0 A
Northern Cakaudrove - 30,077 62.8% 16 0 0 A
Northern Taveuni - 16,401 89.8% 15 1 0 A
Northern Macuata - 65,681 101.3% 14 2 0 R
Eastern Kadavu - 11,805 77.4% 16 0 0 A
Eastern Lomaiviti - 15,142 65.3% 15 1 0 A
Eastern Lomaloma - 2,514 109.3% 15 1 0 A
Eastern Lakeba - 3,494 73.8% 16 0 0 A
All 519,167 82% 279 23 2
DK/NR: Don’t know/No response; D: Decision; A: Accepted; R: Rejected.
https://doi.org/10.1371/journal.pone.0238622.t002
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Surveyed program coverage and reasons for not participating in LF-MDA
The estimated LF-MDA program coverage for the 3 divisions was 92% (95% CI: 87.4–94.7).
This is higher than the reported administrative coverage of 82% [27]. There was no significant
difference in coverage estimates across divisions, sexes, age groups, or household size catego-
ries (Table 1). The estimated program coverage for the urban population was significantly
lower than that for rural residents (P = 0.026).
The most common reasons for persons not participating in the LF-MDA were that they
were absent during the house-to-house drug distribution, that they did not have enough infor-
mation about collection days/sites, or that the drug distributors did not visit their homes/com-
munity. (Fig 3).
Participants’ experience with the LF-MDA drug distributors
At least nine out of 10 of the 304 surveyed participants claimed to have swallowed the medicine
during the house-to-house distribution process (Table 3). About 88% could recall receiving
the volunteers in their homes, and 98% were offered the drugs. More than ten percent of those
participants who were offered the drugs claimed to have not received sufficient information
on the medications from the drug distributors. Most of the participants (96%) verbally con-
firmed having swallowed the drugs, with 65% further recalling doing it in the presence of the
drug distributors, and a further 59% remembering their fingernail being marked with indelible
marker. About one-third felt unwell or weak after swallowing the drugs. Overall the delivery
strategy for the 10th round of LF-MDA was considered satisfactory by community members,
but the level of satisfaction was significantly lower in the group that missed out on the
LF-MDA (P = 0.037). Nine of the 22 unsatisfied participants interviewed would prefer to
Fig 3. Number of people with reasons for non-participating in the LF-MDA in the Central, Northern, and Eastern Divisions of Fiji.
https://doi.org/10.1371/journal.pone.0238622.g003
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collect their medications from health centers, six requested to receive it from their homes, and
two would prefer medications dispensed at the workplace or school instead of the home. One
participant agreed with the strategy but felt that more detailed explanations needed to be pro-
vided by the drug distributors.
Almost all (90%) of the interviewees knew the purpose of the drug distribution, and 70%
were aware of the complications associated with lymphatic filariasis (Table 4). A further 77%
knew about the transmission of the disease by mosquitoes. However, there was no significant
difference in the level of knowledge between participants that swallowed the drugs and those
Table 3. Participants’ experience with the 10th round of LF-MDA in the Central, Northern, and Eastern Divisions
of Fiji.
Characteristic Percent� 95% CI�
Swallowed the drugs (n = 279) 91.7 87.4–94.7
• Via house-to-house visit (n = 253) 90.5 85.5–93.9
• Distributed via other places (workplaces, markets, or health centers) (n = 26) 9.5 6.1–14.5
My house was visited by the volunteer (n = 266) 88.1 83.2–91.7
• Drugs were delivered and offered by the volunteer (n = 259) 97.9 95.2–99.1
• Drugs were not delivered (n = 7) 2.1 0.9–4.8
• The volunteers provided enough explanations at their visit (n = 236) 87.8 78.7–93.4
• No, they did not provide enough explanations (n = 28) 12.2 6.6–21.3
I swallowed the drugs when offered by the volunteer who visited the house (n = 249) 96.2 92.3–98.1
• My swallowing was directly observed (n = 165) 64.5 55.1–72.9
• My swallowing was not directly observed (n = 82) 34.8 26.4–44.2
• Don’t recall (n = 2) 0.7 0.2–2.9
• They marked my nail (n = 154) 59.1 49.4–68.1
• They did not mark my nail (n = 93) 40.3 31.3–50.0
• Don’t recall (n = 2) 0.6 0.1–3.3
Felt unwell after swallowing the drugs (n = 105) 35.9 28.5–43.9
Satisfied with the LF-MDA strategy (n = 279) 92.3 87.9–95.2
�Weighted based on the proportion of sub-divisional per divisional population size.
https://doi.org/10.1371/journal.pone.0238622.t003
Table 4. Survey respondents’ levels of knowledge, practice, and attitude associated with LF-MDA in the Central,
Northern, and Eastern Divisions of Fiji.
Characteristic Percent� 95% CI� P-value
Knew what the LF-MDA drugs were for (n = 274) 90.0 82.0–94.7
Among those who swallowed (253/279) 90.9 81.9–95.6 0.5627
Among those who did not swallow (21/25) 81.0 56.9–93.2
Knew what the complications of LF were (n = 202) 69.6 61.8–76.4
Among those who swallowed (186/279) 70.1 61.7–77.3 0.0568
Among those who did not swallow (16/25) 63.8 41.3–81.5
Knew how LF is transmitted (n = 231) 77.0 68.7–83.6
Among those who swallowed (211/274) 75.9 67.1–83.1 0.091
Among those who did not swallow (20/24) 89.1 73.1–96.1
Informed about the LF-MDA round beforehand (n = 243) 85.7 80.0–90.0
Among those who swallowed (226/274) 87.1 81.2–91.3 0.1503
Among those who did not swallow (17/25) 71.2 48.0–87.0
�Weighted based on the proportion of sub-divisional per divisional population size.
https://doi.org/10.1371/journal.pone.0238622.t004
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who did not. At least 86% of the participants could recall receiving information about the
LF-MDA round before the distribution (Table 4). The sources of information about the
LF-MDA round are presented in Fig 4.
Discussion
Population-based assessment of post-MDA coverage is an essential tool for measuring the
effectiveness of MDA interventions and exploring the barriers to services [28]. These surveys
provide practical information for decision makers that is not dependent on population data,
which may not always be reliable [29]. We conducted a survey to determine which medical
areas in Suva and the sub-divisions in the rest of the 3 divisions targeted by the LF-MDA 10th
round did not achieve at least 80% program coverage. Despite an overall high LF-MDA pro-
gram coverage, the LQAS results revealed the existence of pockets of low coverage at medical
and sub-divisional levels: more than a third of the 19 lots were identified as areas with probable
low coverage; this information could provide the basis for strategies to increase coverage and
reach targets.
Most of the lots identified as having unacceptable coverage, except the Naitasiri sub-divi-
sion, were in urban areas: five medical areas in Suva, the capital city, and the other sub-divi-
sion, Macuata, which is an urban centre of the 2nd largest island. This is in line with the
findings from other studies showing greater difficulty in achieving LF-MDA coverage goals in
urban canters than in rural ones [30–32, 33]. The presence of non-resident populations, lim-
ited ability of the urban dwellers to receive door-to-door treatment, high awareness of the
Fig 4. Sources of information on LF-MDA in the Central, Northern, and Eastern Divisions of Fiji by percentage�. �Proportion and confidence intervals were weighted
based on the proportion of sub-divisional per divisional population size.
https://doi.org/10.1371/journal.pone.0238622.g004
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infection but low perception of its risks, and low compliance due to insufficient information,
have been identified as barriers to MDA success in urban areas [30]. Hence, it is useful to look
at the disaggregated data for urban settings, as we did in our study, since the evidence shows
that a large number of unreached targets often could reside especially in rapidly expanding
urban slums [34]. In contrast to urban areas, in the Naitasiri sub-division, which is another
failed lot, and the surrounding sub-division of the capital Suva, it is thought that a large por-
tion of the community members were covered in Suva [23, 35], where they spend most of their
time. Hence, we believe that the actual level of service uptake by the residents in that area was
low. However, we cannot rule out the possibility that other variables such as inaccurate regis-
tration of dose delivered (numerator) could act as the main source of the discrepancy, given
that we did not assess the quality of the data on site [21]. In this regard, it would be helpful to
explore additional indicators, such as the number of households registered, and the number of
persons who swallowed the medication as a function of each drug distributor, to see whether
the programme has run efficiently in these low performing areas rather than relying solely on
coverage levels [21].
Discordance between the reported administrative coverage and survey results has been doc-
umented not only in MDA rounds but also in mass vaccination campaigns [28, 36, 37]. In our
study, levels of administrative coverage in these failed lots ranged from 59% to 107%, and
more than a half of them had a reported coverage higher than the national target of 80%,
implying that relying on the reported coverage for mop-up decisions may not reflect the real
situation. Imprecise population estimates (denominator) at lot level due to movement of popu-
lations across lot borders, which can be aggravated in fast growing urban cities, and outdated
censuses can affect the accuracy of the reported coverage figures [38, 39, 40]. Adapting numer-
ator-based data to avoid imprecise denominators for marginalised populations [34], as well as
caution in using solely administrative coverage levels for assessing programme performance
has been widely recommended [29] as complementary measures.
Cluster surveys are used to estimate programme coverage with point estimates, while LQAS
has been used to classify coverage (i.e., generate labels like acceptable/not acceptable) [39]:
LQAS can provide critical information on pockets of areas not necessarily fully covered by the
intervention with a smaller sample size [12]. Depending on levels of expected coverage, cluster
sampling survey methods require sample sizes of the order of hundreds of individuals to
obtain reliable estimates even for the districts surveyed [19, 21]. For instance, if we had identi-
fied pockets with low coverage using standard 30�7 cluster samplings, as we did in our study,
either at the medical area or sub-divisional level, we would have needed at least 19�210 partici-
pants, which is 10-fold our actual sample size. Instead, nesting LQAS in the survey or aggregat-
ing data from LQAS enables one to conduct the study with greater flexibility and obtain more
detailed information by area than with 30-cluster surveys [38]. In this study, LQAS was
embedded in a two-stage random sample to assess LF-MDA program coverage at the sub-pop-
ulation level. Selecting a little more than three hundred participants as the sample actually
increased the feasibility of the survey in the field and provided area-specific information that
could identify pockets with lower coverage.
The present study adapted the standard LQAS technique that has been applied to several
public health programmes, as it was planned before the recent global recommendations for
rapid monitoring of MDA coverage, and coverage evaluation surveys, were made [19–21]. In
fact, our survey design is closer to the supervisor’s rapid coverage monitoring tool [20] than
the 30-cluster coverage survey [19], and the only difference is the sample size of 16 rather than
20 [20]. This rapid monitoring tool was designed to maximize the benefits of LQAS: identify-
ing areas of weak coverage with statistical reliability, differentiating areas of varying coverage
with greater precision, and allowing for trend analysis of intervention quality [13, 41, 42]. In
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the study, we proved that this is a practical methodology since the interpretation of the results
is straightforward and immediate and can be further facilitated by using mobile phones in the
field to improve the timeliness of data collection and reporting [16, 41]. LQAS is useful in
addressing remaining gaps in programme quality, since it helps focus resources on high-risk
areas to prevent the continued transmission of infectious agents [13, 43]. To our knowledge,
this is one of only a small number of studies applying LQAS to assess the coverage of a nation-
wide round of LF-MDA [37].
We also evaluated several aspects of the LF-MDA implementation strategy by exploring lev-
els of drug compliance, reasons for not taking the medication, and the extent of penetration of
social mobilization messages. If verbal reports by participants are considered a reliable source
of information about the receipt of drug treatment [44], then the post-LF-MDA drug coverage
estimated by this survey was 92%, which is higher than the reported administrative coverage of
82% [27]. This implies that the 10th LF-MDA round in Fiji achieved the desired coverage goal
of 80% set by the national programme. Based on the responses of the survey respondents, the
most common reasons for non-participating in the LF-MDA were being absent during the
time of drug distribution and being unaware of the LF-MDA round itself. Other reasons for
not swallowing the medication were either that the drug distributors did not reach the house-
hold, or they had run out of drugs by the time they visited the household due to stock-out.
This is similar to the finding from other studies that the main determinant of low drug uptake
in low-resource settings was not refusals, but rather problems with service organization, such
as awareness of MDA and the length of the drug distribution period [36, 38]. Alternative
options should be planned for the absentees, such as designating nursing stations or health
centers as fixed sites to provide drugs for those who missed the visits, and these should be
available before, during and after the LF-MDA period.
A little more than 90% of participants responded positively concerning the level of satisfac-
tion for the LF-MDA strategy. Disappointingly, more than 1 out of 10 drug distributors did
not provide the survey respondents with sufficient explanation. Moreover, only 65% of the vol-
unteers observed the drug swallowing and only 60% marked the fingernail thereafter. The rea-
sons for not observing drug swallowing were possibly: (1) cultural difficulty faced by the drug
distributors when refusing requests to leave medications for family members who were absent
at the time. Despite training in mock exercises, it was a challenge for mainly young adolescent
drug distributors to politely refuse an older adult requesting medication for family members
in absentia; and (2) the past LF-MDA practice of leaving medication for family members in
absentia was difficult to change, especially when previous drug distributors were not required
to directly observe swallowing. In an attempt to mitigate this situation, mass media messages
were communicated during the pre-LF-MDA sensitization period about leaving ‘no tablets
behind’. However, since less than half the survey participants learned about the LF-MDA
round from these media and a greater proportion learned of it through word of mouth, the
low directly observed swallowing rate is an indication that the message may have not perme-
ated well. Another attempt was made by marking fingernails, as commonly used in polio vacci-
nation campaigns. The uptake of this strategy was limited to two-thirds of the participants,
highlighting the unfamiliarity with the procedure and the need to improve the quality of train-
ing for drug distributors in practicing it.
The 2% of participants who claimed to have not been given the medications during the
LF-MDA period were supposed to be re-visited by drug distributors who ran out of medica-
tions. Despite the instruction to revisit the houses after replenishing the medication supply,
the distributors possibly chose instead to move quickly to other localities. These events were
not uncommon especially with the shortage of albendazole in the field: initially, all volunteers
were given a bottle of 50 mg DEC containing 1,000 tablets and another bottle with a 100 400
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mg albendazole tablets and were instructed to return to a health center for replenishment. The
quantity of DEC would have been sufficient to cover at least 120 people, but they would run
out of albendazole after 100 residents, sooner than after DEC. Since most of the distribution
by drug distributors was through house-to-house visits rather than by fixed-site distribution,
the quantities packaged are likely to affect the individual distributor’s performance. Hence, in
future LF-MDA rounds it would be important to have a sufficient level of buffer stocks at the
periphery, or to re-package medications in matched amounts rather than 1 bottle each, when
the strategy requires a high level of involvement of individual drug distributors providing
house-to-house distribution.
The overall levels of knowledge on LF and its complications of the survey respondents were
high, and no difference was observed between those that swallowed the drugs and those that
did not. More than 80% of the participants were aware of the LF-MDA round in advance and
the figure was slightly higher for those who swallowed the drugs, which showed good perme-
ation of information to the public. The most common source of information on the LF-MDA
round were health workers, indicating the importance of the active engagement of the health
workforce in the successful implementation. Although the main messages communicated dur-
ing the LF-MDA were not explored in detail in our study, it could be more effective to further
stress drug distribution strategy-related information such as dates of distribution, and loca-
tions of pick-up stations when visits are missed. Moreover, it is becoming increasingly popular
to adopt social network services (SNS) to further advertise public health initiatives and pro-
grams. SNS have the potential to extend the reach and efficiency of essential public health ser-
vices by offering a range of multidirectional communication strategies and interactions to plan
and deliver LF-MDA-related messages effectively to the public [45]. SNS should be considered
in future LF-MDA rounds.
This study has several limitations. First, recall bias by the survey participants will not be
negligible, given that it was conducted five months after the LF-MDA round. A possible expla-
nation for the higher value of the estimated program coverage than the reported administrative
coverage is linked to the fact that we relied on verbal reports, which were not validated via
review of the registration booklets. People tend to say yes when they know there is a possibility
of stigmatization if they say no. Hence, in order to reduce such effects, it is recommended to
undertake the evaluation within one month of the end of the LF-MDA round and to introduce
tools for possible verification of verbal reports, such as review of booklets, fingernail marking
or individual drug treatment cards. The fingernail mark used in this study was detected in 60%
of the treated population, and other marks may have faded by the time the survey was con-
ducted. Other areas of improvement include the introduction of an "MDA card" similar to an
immunization card, which is not routinely introduced for MDA mainly due to the associated
costs. Second, there may be a correlation between being at home during the visit of the
LF-MDA drug distributors and being at home for the interview, which could lead to over-esti-
mation of the coverage. Using different sampling methods that are not household-based could
reduce this bias. In addition, this assessment is based on surveying ‘customers’ satisfaction’
with the delivery of services. Additional valuable and meaningful information could be gained
by conducting focus group interviews or narrative surveys with the drug distributors who were
involved in drug distribution [46] or the health staff who supervised them, to investigate the
providers’ point of view [47]. Lastly, the study was designed before the global recommendation
for rapid monitoring of MDA coverage was made available and, as for LQAS, we applied a
smaller sample size with relatively large alpha and beta levels than other studies [16, 21]. This
may have led to incorrect conclusions as to whether coverage levels of individual lots were
acceptable or not. However, we formulated the null hypothesis towards the conservative side,
by assuming less program coverage for the intervention, and requiring strong evidence before
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rejecting the null hypothesis [16]. In this way the decisions made are in the direction of pro-
tecting the population concerned.
Conclusion
Our data indicate that pockets of low coverage existed, based on the LQAS methodology,
which provided action-oriented data at the local level (medical areas or sub-divisions). Drug
compliance and satisfaction of the survey respondents was high, even after repeated LF-MDA
rounds. Hence, a key recommendation is to correlate findings with periodic future LF-MDA
rounds and to strengthen service delivery and logistic arrangements in the lots with low cover-
age. Conducting a timely coverage assessment, such as a focal LQAS survey in these areas with
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